(Q37079678)

1 July 2019

1 reference

6 August 2019

Antiparkinson prodrugs (English)

1 reference

1 July 2019

pharmaceutical preparation

main subject

1 reference

6 August 2019

1

1 reference

1 July 2019

author name string

Piera Sozio

series ordinal

2

1 reference

1 July 2019

Laura Serafina Cerasa

series ordinal

3

1 reference

1 July 2019

language of work or name

English

0 references

publication date

16 January 2008

2 references

1 July 2019

6 August 2019

2 references

1 July 2019

6 August 2019

13

1 reference

1 July 2019

issue

1

1 reference

1 July 2019

page(s)

46-68

1 reference

1 July 2019

Creative Commons Attribution 4.0 International

copyright license

start time

16 January 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Expanding insights of mitochondrial dysfunction in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Protective and symptomatic strategies for therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Clinical pharmacokinetics of anti-parkinsonian drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Dimeric L-dopa derivatives as potential prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Role of organic cation transporters in dopamine uptake across olfactory and nasal respiratory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Synthesis and pharmacology of centrally acting dopamine derivatives and analogs in relation to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Site-specific, sustained release of drugs to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Facilitative glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Design and synthesis of a novel L-dopa-entacapone codrug

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Rational approach to discover multipotent anti-Alzheimer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Esters of apomorphine and N,N-dimethyldopamine as agonists of dopamine receptors in the rat brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Diester derivatives as apomorphine prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Hydrolysis of diester prodrugs of apomorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Long lasting stimulation of locomotor activity produced by the intraventricular injection of a cyclic analogue of dopamine into conscious mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Differential activation by some 2-aminotetralin derivatives of the receptor mechanisms in the nucleus accumbens of rat which mediate hyperactivity and stereotyped biting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

3,4-disubstituted phenyliminoimidazolidines as potential prodrugs of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (DPI).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Carbamate ester derivatives as potential prodrugs of the presynaptic dopamine autoreceptor agonist (-)-3-(3-hydroxyphenyl)-N-propylpiperidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Orally Active Carbamate Prodrugs of the Selective Dopamine Agonist N-0437: In-vivo Activities in the 6-OHDA Turning Model and In-vitro Activities

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Orally active analogues of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one: synthesis and pharmacological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Extremely potent orally active benzo[g]quinoline analogue of the dopaminergic prodrug: 1-propyl-trans-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo-[g]quinolin-6-one [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data

21 January 2018

2 references

https://api.crossref.org/works/10.3390%2FMOLECULES13010046

21 January 2018

12 December 2020

L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease

1 reference

12 December 2020

Improved delivery through biological membranes. 4. Prodrugs of L-dopa

1 reference

12 December 2020

Pro-drugs of isoniazid: synthesis and diffusion characteristics of acyl derivatives.

1 reference

12 December 2020

Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

1 reference

12 December 2020

Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine

1 reference

12 December 2020

Improved delivery through biological membranes. 13. Brain-specific delivery of dopamine with a dihydropyridine in equilibrium with pyridinium salt type redox delivery system

1 reference

12 December 2020

The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia

1 reference

12 December 2020

Control of on/off phenomenon by continuous intravenous infusion of levodopa

1 reference

12 December 2020

Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.

1 reference

12 December 2020

Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model

1 reference

12 December 2020

Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration

1 reference

12 December 2020

Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms

1 reference

12 December 2020

Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs

1 reference

12 December 2020

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

1 reference

12 December 2020

Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability, and bioconversion

1 reference

12 December 2020

Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents

1 reference

12 December 2020

Parkinson's disease: prospects for improved drug therapy

1 reference

12 December 2020

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

12 December 2020

Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies

1 reference

12 December 2020

A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine

1 reference

12 December 2020

Levodopa methyl ester treatment of Parkinson's disease

1 reference

12 December 2020

L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease

1 reference

12 December 2020

Peptide drug delivery into the central nervous system.

1 reference

12 December 2020

Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs

1 reference

12 December 2020

Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection

1 reference

12 December 2020

The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats

1 reference

12 December 2020

L-dopa level in plasma, primary condition for the kinetic effect

1 reference

12 December 2020

3,4-0-diacyl derivatives of dopamine

1 reference

12 December 2020

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs

1 reference

12 December 2020

Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients

1 reference

12 December 2020

Dopamine receptors: from structure to function

1 reference

12 December 2020

Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone

1 reference

12 December 2020

Dopaminergic prodrugs: brain concentrations and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters

1 reference

12 December 2020

Synthesis and antireserpine activity of peptides of L-dopa

1 reference

12 December 2020

10.3390/MOLECULES13010046

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6244951

1 reference

1 July 2019

PubMed publication ID

18259129

1 reference

1 July 2019